Critical Appraisal: What a Viral Obesity Post Gets Right, and What It Misses
A recent LinkedIn post on insulin resistance and obesity has circulated widely among physicians and health professionals. It makes several claims worth examining, because some hold up well and others need more nuance than a social post allows.
The mechanism is broadly correct but oversimplified. The post states that insulin resistance drives fat storage, inflammation, and chronic disease years before diagnosis. This tracks with the pathophysiology I see in clinic every week. Insulin resistance precedes type 2 diabetes and cardiovascular disease by years, sometimes decades. But calling it the sole driver skips over genetics, sleep debt, chronic stress, and gut microbiome shifts, all of which interact with insulin signaling rather than sit downstream of it.
The biology is more tangled than one pathway. The disease list is accurate, but the framing needs a citation. Heart disease, stroke, type 2 diabetes, PCOS, and erectile dysfunction all carry strong, well-replicated links to obesity and insulin resistance. Cancer and Alzheimer’s disease show real but weaker and more mechanistically debated associations. A post that presents all eight conditions with equal certainty blurs a distinction your patients deserve to understand.
“People rarely die from obesity itself” is true, and also a little misleading. Obesity rarely appears as the immediate cause of death on a certificate. But that framing risks softening the message for patients who need urgency now, not a decade from now. In my practice, I treat obesity as the upstream driver, not a bystander waiting for its downstream disease to show up first.
The 1 in 4 children with fatty liver disease figure needs context. That number comes from cohorts of children who already have obesity, not the general pediatric population. Presented without that qualifier, it reads far more alarmingly than the underlying data support, even though the underlying trend is genuinely concerning.
The strongest part of the post is the question it asks, not the answer it gives.
Why does healthcare wait for a diagnosis before acting on insulin resistance? I agree with the premise. Where I disagree is the implied choice between prevention and prescribing.
In my clinic, semaglutide and tirzepatide are prevention tools. SELECT showed a 20% cut in major cardiovascular events in patients with obesity and cardiovascular disease.
That is a metabolic intervention, not a shortcut around one. The future of medicine will not belong to physicians who prescribe drugs instead of addressing metabolism, or to those who address metabolism instead of prescribing drugs. It will belong to those who do both, with the patient owning the plan alongside us.